Asif Khaliq | Pharmaceutical Sciences | Best Researcher Award

Published on by Shen Awards

Dr. Asif Khaliq | Pharmaceutical Sciences | Best Researcher Award

Dr. Asif Khaliq is a distinguished clinical pharmacist and public health researcher with extensive experience across Pakistan and Australia. With over 15 years of cumulative expertise in pharmacy practice, healthcare management, and academic research, he has played pivotal roles in both hospital settings and global health research initiatives. Dr. Khaliq currently serves as a Clinical Pharmacist at Atherton Hospital, Queensland Health, where he contributes to medication reconciliation, patient consultation, and therapeutic drug monitoring. His broad qualifications in pharmacy, public health, and health management uniquely position him at the intersection of clinical service and evidence-based research. Notably, he has authored around 30 peer-reviewed journal articles and has presented his work at several international conferences. His commitment to improving patient care is reflected in his involvement in projects on antimicrobial stewardship, immunization safety, medication cost optimization, and community health surveillance. A registered pharmacist in both Australia and Pakistan, Dr. Khaliq continues to expand his professional credentials through ongoing training and professional development. His multidisciplinary knowledge and dedication to collaborative, data-driven healthcare improvement make him a leading candidate for honors in research and clinical excellence.

Professional Profile

Education

Dr. Asif Khaliq possesses a diverse and robust academic background that integrates pharmacy, health management, and public health. He earned his Doctor of Pharmacy (PharmD) from the University of Karachi in 2009, laying a solid foundation in pharmaceutical sciences. He later pursued an MBA in Health Management from the Institute of Business Management (IoBM), Karachi, in 2014, equipping him with managerial and strategic skills essential for healthcare administration. In 2017, he obtained a Master of Public Health (MPH) from Baqai Medical University, further expanding his expertise into population health, disease prevention, and health systems. Most recently, he completed a Ph.D. in Public Health at Queensland University of Technology (QUT), Australia, in 2023. His doctoral research focused on critical issues in public health, integrating practical clinical knowledge with research methodologies. In addition to these core degrees, Dr. Khaliq has cleared the Knowledge Assessment of Pharmaceutical Sciences (KAPS) by the Australian Pharmacy Council and has demonstrated English language proficiency through PTE Academic. His academic trajectory reflects a commitment to lifelong learning and interdisciplinary mastery, qualifying him to address complex healthcare challenges at both clinical and systemic levels.

Professional Experience

Dr. Khaliq’s professional journey spans multiple sectors, including hospital pharmacy, public health research, and academic instruction. Currently, he serves as a Clinical Pharmacist at Atherton Hospital under Queensland Health, where he provides vital services including medication review, drug interaction management, therapeutic optimization, and discharge planning. His responsibilities also involve daily clinical monitoring and interdisciplinary collaboration with physicians and nursing staff. Previously, he held pharmacist roles at Infinity Pharmacy Earlville Upper, Allora Pharmacy, and Boulder Pharmacy across Queensland, Australia. In these roles, he handled immunization services, controlled substance management, MedsChecks, and patient counseling. Notably, Dr. Khaliq served as a Research Coordinator at Aga Khan University Hospital, Pakistan, where he supervised international clinical trials and led efforts in typhoid outbreak investigations. He also worked in various pharmacist roles at Aga Khan University Hospital’s emergency and pediatrics departments, gaining critical experience in medication reconciliation, IV-to-oral drug conversions, and poison management. His early career included logistics and inventory roles with Médecins Sans Frontières, further enriching his understanding of pharmaceutical supply chains. This comprehensive experience makes Dr. Khaliq uniquely capable of blending clinical insights with research acumen and operational excellence.

Research Interests

Dr. Asif Khaliq’s research interests lie at the nexus of clinical pharmacy, public health, and healthcare systems management. He is particularly focused on areas such as antimicrobial stewardship, vaccine safety and immunogenicity, medication adherence, and cost-effective therapeutic strategies. During his Ph.D. studies at Queensland University of Technology, he explored healthcare outcomes linked to pharmacological practices and population-level health interventions. His work frequently integrates health surveillance, epidemiology, and evidence-based medicine to address real-world challenges in both hospital and community settings. He has led or contributed to major research projects including randomized controlled trials on antibiotic use in pediatric diarrhea and typhoid outbreak control. In recent roles, he has also investigated adverse events following immunization (AEFI), resistance patterns in Salmonella species, and systematic reviews on outbreak trends in developing regions. Dr. Khaliq is deeply committed to identifying research gaps in healthcare delivery and prescribing patterns, aiming to improve policy, patient outcomes, and clinical protocols. His interdisciplinary research interests reflect his training in pharmacy, health management, and public health, empowering him to make meaningful contributions to both academic literature and healthcare practice.

Research Skills

Dr. Khaliq possesses a broad and advanced set of research skills that enhance his ability to contribute to multidisciplinary studies and clinical investigations. He is highly proficient in clinical trial management, including participant recruitment, data collection, and adverse event reporting. His expertise extends to secondary data analysis, especially in reviewing hospital records, surveillance data, and immunization outcomes. He is experienced in systematic reviews and meta-analyses, utilizing medical databases and analytical frameworks to synthesize health evidence. Dr. Khaliq also brings strong capabilities in pharmacovigilance, therapeutic drug monitoring, and drug utilization evaluations. In the realm of academic publishing, he has served as a guest editor and peer reviewer, contributing to journal special issues and maintaining scientific rigor. He is adept at grant proposal development, contributing to multiple research applications during his tenure at academic and healthcare institutions. Moreover, his familiarity with health informatics tools—such as Micromedex, MedAdvisor, and clinical guidelines—enables him to integrate real-time data with clinical decision-making. His research skills are complemented by his teaching experience and mentorship, allowing him to train future researchers and practitioners in evidence-based methods.

Awards and Honors

Dr. Asif Khaliq has garnered recognition for his dedication to public health research and pharmaceutical practice through various academic and professional achievements. He was a selected speaker at notable international forums such as the IMPACT MAKER 2020 conference in Brisbane, where he presented novel research on coexisting forms of malnutrition. His earlier work on poisoning case management was also showcased at the 4th FMIC Conference in Kabul. At the 11th International Coalition Against Typhoid Conference in Hanoi, Vietnam, Dr. Khaliq presented two critical posters on typhoid drug resistance and outbreak investigation, underscoring his commitment to infectious disease research. He has published approximately 30 peer-reviewed papers, several of which have appeared in reputable international journals. While formal individual awards may not be listed, his multiple research leadership roles, international conference engagements, and responsibilities as a guest editor reflect his strong reputation in both academic and healthcare sectors. His continuous pursuit of professional certifications, including immunization and UTI management, also highlights a dedication to clinical excellence. These accomplishments collectively underscore his potential as an award-worthy contributor to global health and pharmacy practice.

Conclusion

In conclusion, Dr. Asif Khaliq exemplifies the ideal profile of a clinical researcher who bridges academic insight with frontline healthcare delivery. His academic credentials across pharmacy, health management, and public health are complemented by his extensive experience in clinical pharmacy settings in both Pakistan and Australia. Through his research on antibiotic use, immunization safety, and medication optimization, Dr. Khaliq addresses key healthcare challenges relevant to global and regional populations. He demonstrates not only technical knowledge but also leadership in research coordination, interdisciplinary collaboration, and scientific communication. His professional ethos is defined by evidence-based practice, patient-centered care, and continual improvement. As a registered pharmacist in two countries and an active participant in international academic dialogues, Dr. Khaliq is well-positioned to further influence policy, education, and clinical standards. His consistent pursuit of professional development, publication, and mentorship reflects a commitment to excellence that aligns with the objectives of the Best Researcher Award. Recognizing his contributions would not only honor individual achievement but also highlight the critical role of pharmacist-researchers in shaping modern healthcare systems.

Publications Top Notes

1. Mission of Polio Eradication in Pakistan – A Review on Challenges and Future Recommendations

  • Year: 2025

  • Source: New Microbes and New Infections (Open Access)

2. Adherence to Complementary Feeding Indicators and Their Associations with Coexisting Forms of Malnutrition in Children Aged Between 6 to 23.9 Months of Age

  • Year: 2023

  • Source: Journal of Public Health

 

Cem Calışkan | Pharmaceutical Science | Best Researcher Award

Published on by Shen Awards

Dr. Cem Calışkan | Pharmaceutical Science | Best Researcher Award

R&D Manager from World Medicine, Turkey

Dr. Cem Çalışkan is an accomplished R&D Manager and pharmaceutical researcher with a distinguished background in analytical chemistry, method development, and regulatory compliance. His professional journey is marked by extensive contributions to the pharmaceutical industry, particularly in analytical method validation, formulation development, and laboratory accreditation processes. With over a decade of progressive experience, Dr. Çalışkan has held key roles at leading pharmaceutical organizations including World Medicine and Neutec İlaç, consistently driving innovation and excellence in pharmaceutical R&D. His academic background features a Ph.D. in Analytical Chemistry from Yıldız Technical University, complemented by a Master’s degree in Organic Chemistry and ongoing Executive MBA studies at Istanbul University, reflecting a multidisciplinary approach to science and leadership. Dr. Çalışkan’s portfolio includes several peer-reviewed publications in top scientific journals, where he explores themes such as nitrosamine detection, impurity profiling, stability-indicating methods, and in-vitro drug release. His research not only addresses critical analytical challenges but also aligns with global regulatory standards. With a passion for mentoring, scientific rigor, and innovation, Dr. Çalışkan exemplifies the integration of academic excellence and industrial impact, making him a strong candidate for scientific recognition at the international level.

Professional Profile

Education

Dr. Cem Çalışkan has a comprehensive and interdisciplinary educational background that has shaped his expertise in analytical and organic chemistry as well as pharmaceutical development. He earned his Doctor of Philosophy (Ph.D.) in Analytical Chemistry from Yıldız Technical University between 2018 and 2022, where he focused on advanced analytical techniques and pharmaceutical applications. His doctoral work provided the foundation for several high-impact scientific publications and patents in method validation and impurity analysis. To complement his scientific expertise with managerial insight, Dr. Çalışkan is currently pursuing an Executive MBA at Istanbul University (2024–present), focusing on strategic business management and leadership in the pharmaceutical industry. His academic journey also includes a Master of Science in Organic Chemistry from Sakarya University (2014–2016), where he deepened his understanding of chemical reactions, drug formulation, and molecular mechanisms. He holds a Bachelor of Science in Chemistry from Uludağ University (2003–2009), which laid the initial groundwork for his professional path in R&D. This strong academic progression, spanning both the sciences and management, enables Dr. Çalışkan to bridge the gap between innovative research and strategic decision-making in the pharmaceutical sector.

Professional Experience

Dr. Cem Çalışkan’s professional experience reflects a sustained commitment to innovation and quality in pharmaceutical research and development. Since 2020, he has been serving as the R&D Manager at World Medicine, where he leads cross-functional teams in analytical development, method validation, and compliance with international regulatory standards. In this role, he initiated the patented WMINOLAB analytical service model, exemplifying his vision for high-quality, independent R&D frameworks. Prior to this, from February to August 2020, he held the position of R&D Analytical Development Chief at the same organization, coordinating sustainable business process models, documentation systems, and team development initiatives. Between 2013 and 2020, Dr. Çalışkan worked as an R&D Responsible Specialist, playing a critical role in analytical method development, stability testing, and responding to regulatory queries from global authorities. Earlier in his career, he served as a Process Development Analyst at Neutec İlaç (2011–2013), where he conducted formulation trials, transfer validations, and documentation for CTD Module III. These roles have not only honed his technical capabilities but also highlighted his strategic thinking, regulatory insight, and project management skills in both domestic and international pharmaceutical landscapes.

Research Interests

Dr. Cem Çalışkan’s research interests center on pharmaceutical analytical chemistry, with a special focus on developing novel methods for impurity profiling, drug stability studies, and nitrosamine risk assessment. He is deeply engaged in creating robust and regulatory-compliant analytical methodologies using cutting-edge instruments such as LC-MS/MS, RP-HPLC, and FTIR spectroscopy. His scientific inquiries aim to improve the accuracy, reproducibility, and efficiency of pharmaceutical testing methods, ensuring safer and more effective drug formulations. A key area of his work involves validating stability-indicating methods for various drug compounds, exploring the physicochemical behavior of active pharmaceutical ingredients (APIs) and excipients under stress conditions. He is also involved in studies on in-vitro drug release, polymer membrane permeability, and analytical compatibility of formulation components. In recent years, Dr. Çalışkan has broadened his scope to include the assessment of genotoxic impurities and packaging-related contaminant analysis, which are critical in modern pharmaceutical safety regulations. His interest in bridging laboratory innovation with regulatory frameworks is reflected in his leadership of accredited research labs and method development teams. This intersection of research excellence and industry relevance defines his contribution to the evolving landscape of pharmaceutical sciences.

Research Skills

Dr. Cem Çalışkan possesses a broad and advanced skill set in pharmaceutical R&D, particularly in the analytical domain. His technical proficiency includes the use of LC-MS/MS, RP-HPLC, FTIR, UV-Vis spectroscopy, and gravimetric analysis for method development, validation, and impurity determination. He is well-versed in Good Laboratory Practice (GLP) and has led numerous method validation studies, including for high-risk pharmaceutical substances like nitrosamines and complex impurities. His skills extend to process optimization, formulation compatibility testing, and the analytical transfer of drug products across laboratories and regulatory environments. Dr. Çalışkan also excels in scientific documentation, protocol writing, and preparation of CTD Module III files for regulatory submission. Beyond technical expertise, he has notable experience in project management, cross-departmental coordination, and team training, equipping him to lead dynamic research teams. His communication skills support effective regulatory correspondence with ministries and international partners, while his analytical thinking aids in critical decision-making across all stages of pharmaceutical development. Combined, these research skills make him not only a technically sound researcher but also an effective scientific leader.

Awards and Honors

While specific awards and honors are not listed in his current profile, Dr. Cem Çalışkan’s career accomplishments reflect a reputation for research excellence and industrial innovation. His leadership in the development and implementation of WMINOLAB, a patented analytical service platform within World Medicine, stands as a testament to his ability to deliver novel, scalable solutions to industry-wide challenges. His publications in reputable journals such as the Journal of Pharmaceutical Sciences, European Journal of Mass Spectrometry, and Journal of AOAC International showcase his academic influence and contributions to pharmaceutical quality control and safety. Additionally, Dr. Çalışkan has played a crucial role in securing and maintaining laboratory accreditations, further evidencing his standing in the professional R&D community. With continued recognition through publications, cross-functional leadership roles, and innovation in analytical techniques, it is evident that he is well-positioned for formal accolades in both industrial and academic circles. Nomination for a Best Researcher Award would be a fitting acknowledgment of his significant impact on pharmaceutical research and method validation at both national and international levels.

Conclusion

Dr. Cem Çalışkan represents a compelling candidate for the Best Researcher Award, bringing together scientific rigor, innovative thinking, and impactful leadership in the pharmaceutical sector. His multi-tiered education, from chemistry through analytical science to business management, empowers him to operate effectively at the intersection of research, industry, and regulation. His extensive experience with analytical method development, impurity profiling, and compliance documentation, along with his proactive approach to laboratory innovation, positions him as a distinguished researcher. His publication record reinforces his scientific credibility, while his managerial roles highlight his ability to lead R&D initiatives with strategic foresight. What sets Dr. Çalışkan apart is not only his technical excellence but also his drive to elevate pharmaceutical research standards in Turkey and beyond. As the industry faces increasing regulatory scrutiny and demands for innovation, his skill set is more relevant than ever. Recognizing his achievements through a Best Researcher Award would honor a career dedicated to advancing analytical science and fostering pharmaceutical innovation, while inspiring emerging researchers to pursue excellence in both academia and industry.

Publications Top Notes

1. Comparison of permeability of topical Cream drug through polymer synthetic membranes of different structures using Franz Cell diffusion test

  • Authors: Cihan Torlak, Müge Güleli, Şevki Kızılok, Remziye Azra Kartop, et al.

  • Year: 2024

  • Journal: Journal of Dispersion Science and Technology

2. Evaluation of a Novel LC‑MS/MS Based Analytical Method for the Risk Assessment of Nitrosamines in Pharmaceutical Products and Packaging Materials

  • Authors: Remziye Azra Kartop, Cihan Torlak, et al. (study led by Kartop and colleagues)

  • Year: 2024

  • Journal: Journal of Pharmaceutical Sciences

3. Simultaneous quantification of tiotropium bromide impurities G + H in capsule formulation by LC‑MS/MS

  • Authors: Not specified in preview

  • Year: 2023

  • Journal: European Journal of Mass Spectrometry